Conference Coverage

Chemotherapy, metabolic pathway may affect CAR T-cell potential

Publish date: March 22, 2018

 

FROM AACR 2018


He had no financial disclosures. This study was supported by the AACR, the Doris Duke Charitable Foundation Clinical Science Development Award, the Jeffrey Pride Foundation Research Award, and the St. Baldrick’s Foundation Scholar Award.

SOURCE: Barrett DM et al. AACR 2018, Abstract 1631.

Pages

Recommended Reading

Pembrolizumab plus SBRT shows promise for advanced solid tumors
MDedge Hematology and Oncology
New model predicts survival in atezolizumab-treated advanced urothelial carcinoma
MDedge Hematology and Oncology
Study: Test for PD-L1 amplification in solid tumors
MDedge Hematology and Oncology
Study explores biological implications of MHC-II expression in tumor cells
MDedge Hematology and Oncology
The T-cell repertoire in NSCLC: Therapeutic implications
MDedge Hematology and Oncology
Objective response rate correlates poorly with overall survival in checkpoint-inhibitor trials
MDedge Hematology and Oncology
Immunotherapy regimen influences inflammatory arthritis presentation
MDedge Hematology and Oncology
Avelumab safety compares with other checkpoint inhibitors
MDedge Hematology and Oncology
DNA repair gene mutations predict response to anti–PD-1/PD-L1 in urothelial cancer
MDedge Hematology and Oncology
Cancer groups offer guidance on immune-related adverse events
MDedge Hematology and Oncology